The Zhitong Finance App learned that Keji Pharmaceutical-B (02171) rose by more than 5%. As of press release, it had risen 5.05% to HK$11.43, with a turnover of HK$7.373 million.

On the news, Keji Pharmaceutical-B announced a summary of the findings of CT1190B (a generic CAR-T candidate product targeting CD19/CD20) for the treatment of relapsed/refractory large B-cell lymphoma, and CT071 (an autologous CAR-T candidate product targeting GPRC5D) for treating recurrent/refractory multiple myeloma (R/R MM) and high-risk newly diagnosed multiple myeloma (HR-NDMM), which were presented at the 68th American Society of Hematology (ASH) Annual Meeting.

The announcement stated that research data for the two candidate products will be displayed in the form of posters at the ASH annual meeting. Research updates on CT0596 (a generic CAR-T candidate product targeting BCMA) for the treatment of R/R MM and primary plasma cell leukemia will be published in a separate company announcement in December 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.